Aldeyra Therapeutics Investor Relations Material
Latest events
Study Update
Aldeyra Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aldeyra Therapeutics Inc
Access all reports
Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company is engaged in advancing its pipeline of drug candidates, which target diseases caused by inflammation and tissue damage. Aldeyra's approach is centered on modulating immune responses to treat conditions such as ocular and systemic inflammatory diseases. Its lead therapeutic areas include ophthalmology, with treatments aimed at conditions like dry eye disease and allergic conjunctivitis. The company's goal is to provide new treatment options for diseases with limited or inadequate therapies. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
ALDX
Country
🇺🇸 United States